JP2025505642A5 - - Google Patents

Info

Publication number
JP2025505642A5
JP2025505642A5 JP2024546404A JP2024546404A JP2025505642A5 JP 2025505642 A5 JP2025505642 A5 JP 2025505642A5 JP 2024546404 A JP2024546404 A JP 2024546404A JP 2024546404 A JP2024546404 A JP 2024546404A JP 2025505642 A5 JP2025505642 A5 JP 2025505642A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
antibody
administered
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024546404A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025505642A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2023/051076 external-priority patent/WO2023148702A1/en
Publication of JP2025505642A publication Critical patent/JP2025505642A/ja
Publication of JP2025505642A5 publication Critical patent/JP2025505642A5/ja
Pending legal-status Critical Current

Links

JP2024546404A 2022-02-07 2023-02-07 Egfr/met二重特異性抗体で処置された患者における注入関連反応を低減するための方法 Pending JP2025505642A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263307375P 2022-02-07 2022-02-07
US63/307,375 2022-02-07
US202263389042P 2022-07-14 2022-07-14
US63/389,042 2022-07-14
PCT/IB2023/051076 WO2023148702A1 (en) 2022-02-07 2023-02-07 Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies

Publications (2)

Publication Number Publication Date
JP2025505642A JP2025505642A (ja) 2025-02-28
JP2025505642A5 true JP2025505642A5 (cg-RX-API-DMAC7.html) 2026-01-21

Family

ID=85278233

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024546404A Pending JP2025505642A (ja) 2022-02-07 2023-02-07 Egfr/met二重特異性抗体で処置された患者における注入関連反応を低減するための方法

Country Status (10)

Country Link
US (1) US20230250195A1 (cg-RX-API-DMAC7.html)
EP (1) EP4476255A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025505642A (cg-RX-API-DMAC7.html)
KR (1) KR20240146675A (cg-RX-API-DMAC7.html)
AU (1) AU2023215753A1 (cg-RX-API-DMAC7.html)
CA (1) CA3251417A1 (cg-RX-API-DMAC7.html)
IL (1) IL314756A (cg-RX-API-DMAC7.html)
MX (1) MX2024009701A (cg-RX-API-DMAC7.html)
TW (1) TW202342057A (cg-RX-API-DMAC7.html)
WO (1) WO2023148702A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025185602A1 (en) * 2024-03-05 2025-09-12 Hansoh Bio Llc Immunoconjugates and pharmaceutical uses thereof
WO2026038160A1 (en) * 2024-08-13 2026-02-19 Janssen Biotech, Inc. Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
AU2005250484B2 (en) 2004-06-04 2011-08-11 Genentech, Inc. EGFR mutations
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
CN101952312A (zh) 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
AU2012256281B2 (en) * 2011-05-16 2017-06-15 Genzyme Corporation Induction of immune tolerance by using methotrexate
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
KR102373193B1 (ko) 2012-11-21 2022-03-10 얀센 바이오테크 인코포레이티드 이중특이성 EGFR/c-Met 항체
EP3929190B1 (en) 2014-10-13 2024-12-25 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities
BR112019010020A2 (pt) 2016-11-17 2019-08-20 Univ Texas compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20
MY208668A (en) * 2019-05-14 2025-05-23 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
WO2020240434A1 (en) * 2019-05-28 2020-12-03 Janssen Biotech, Inc. Method of providing safe administration of an anti-cd40 antibody
US20230322933A1 (en) * 2020-06-04 2023-10-12 Bioinvent International Ab Model for prediction of tolerability issues in connection with intravenous administration of therapeutic antibodies
US20230174677A1 (en) * 2021-11-16 2023-06-08 Janssen Biotech, Inc. Use of Approved Bispecific EGFR and Met Specific Antibody Drug Product to Treat Non-Small Cell Lung Cancer (NSCLCL)

Similar Documents

Publication Publication Date Title
US12258411B2 (en) Anti-CCR8 antibodies and uses thereof
KR101931591B1 (ko) 항-il-23 항체
US8552157B2 (en) c-Kit antibodies and uses thereof
JP2023515271A5 (cg-RX-API-DMAC7.html)
US20260062493A1 (en) Antibody Targeting BCMA, Bispecific Antibody, And Use Thereof
KR102731863B1 (ko) 인간 카나비노이드 1(cb1) 수용체 결합 항체
JP2019531273A5 (cg-RX-API-DMAC7.html)
US20140186377A1 (en) Prostaglandin e2 binding proteins and uses thereof
JP2017514461A5 (cg-RX-API-DMAC7.html)
RU2013155906A (ru) Антитела анти-angptl3 и их применение
JP2023542291A5 (cg-RX-API-DMAC7.html)
JP2022512875A5 (cg-RX-API-DMAC7.html)
JP2025500784A5 (cg-RX-API-DMAC7.html)
JP2024544523A5 (cg-RX-API-DMAC7.html)
WO2017059813A1 (zh) 抗乙肝表面抗原的抗体及其用途
JP2024516698A5 (cg-RX-API-DMAC7.html)
FI4244252T3 (fi) Kroonisen obstruktiivisen keuhkosairauden hoito anti-interleukiini-33-vasta-aineella
JP6663910B2 (ja) 抗TNF−α抗体療法を受けた乾癬患者を治療するための方法
JP2021529766A5 (cg-RX-API-DMAC7.html)
JP2021523138A5 (cg-RX-API-DMAC7.html)
JP2024525870A5 (cg-RX-API-DMAC7.html)
EP3911414A1 (en) Antibodies to ebola virus glycoprotein
CA3251417A1 (en) METHODS FOR REDUCING PERFUSION-RELATED REACTIONS IN PATIENTS TREATED WITH EGFR/MET BISPECIFIC ANTIBODIES
JP2017515843A5 (cg-RX-API-DMAC7.html)
JP2023546504A5 (cg-RX-API-DMAC7.html)